

# NEWSLETTER May - June 2020

## CEO's greetings

Back in the days, Finland used to be 'closed for July' due to vacations. This peculiar year, however, the end of June seems to bring colleagues back to the office! Most restrictions have been lifted in Finland following a steady decline in new Covid-19 cases. So, we also decided at Herantis to have a first get-together in June. Staying safely out-doors, it was wonderful to see everyone again in real-life!

In the meanwhile, our team has kept working hard under the pandemic to keep our important projects on track. Our ecosystem continues to function well too. As a proof, we executed a funding round raising 6.8 MEUR in a matter of weeks, based on a fully virtual roadshow. We are really happy to introduce Sweden's AP4 as a new shareholder.

The end of June marks an important change at Herantis: Dr. Craig Cook, an internationally experienced biotech CEO, steps in as our new CEO! The departing CEO, Pekka Simula, continues as a Senior Advisor to ensure fluency of the well-planned transition. Look forward to the next newsletter with Craig's first greetings!

## CLINICAL STUDIES

- **Breast Cancer Associated Lymphedema:** Phase 2 study AdeLE is fully recruited. Results are expected in Q1/21 after a 12-month blinded follow-up. See [Lymfactin website](#) for details.
- **Parkinson's disease:** Phase 1-2 study with CDNF is fully recruited. Based on 6-month results CDNF is safe with encouraging biological signals of neurorestoration in some patients. 12-month results are expected in Q3/20.
- **Breast Cancer Associated Lymphedema:** Phase 1 study is in long-term follow-up. For 12-month safety review please refer to the scientific article by Hartiala et al, JPRAS 2020.

## PLANNED ACTIVITIES

- We have significantly reduced our investor events due to the pandemic. Virtual events will continue as planned.
- **Half-year report**, 27 Aug 2020
- **12-month data from Phase 1-2 clinical study with CDNF in Parkinson's disease**, Q3/2020.
- **Pareto Healthcare Conference**, 3 Sep 2020 in Stockholm: Company presentation to Swedish investors
- **Seminar "World's first clinical trial with CDNF: Aiming for a breakthrough in Parkinson's"** webcast 18 Nov 2020
- **Topline data of Phase 2 clinical study with Lymfactin® in Breast Cancer Associated Lymphedema**, Q1/2021

## Herantis of the month



Finland waking up to a post-covid world! Our first get-together since March: Wonderful dinner, safely outdoors, in lovely June weather.

Keep up-to-date on Herantis:



Contact us



@Herantis Pharma



Subscribe

## Highlights from team

As we are preparing a Phase 3 study with our Lymfactin® gene therapy, we reached out for lymphedema patients to increase the understanding on how the disease impacts their daily lives. Huge thanks to lymphedema patient group [LE&RN](#) for their support!

And we are excited to announce, together with the European Parkinson's advocacy [EPDA](#), a seminar to be held on Nov 18<sup>th</sup> discussing the clinical results with CDNF: [World's first clinical trial with CDNF: Aiming for a breakthrough in Parkinson's](#). Details will follow.

## Topics of interest

The first scientific article was published on our Lymfactin® clinical study! Hartiala et al: [Phase 1 Lymfactin® Study: Short-term Safety of Combined Adenoviral VEGF-C and Lymph Node Transfer Treatment for Upper Extremity Lymphedema](#). Journal of Plastic, Reconstructive & Aesthetic Surgery.

## Herantis in the news

DDN News' article [One step at a time](#) discusses Herantis' interim 6 month data with CDNF in Parkinson's disease.

Edison released an update on their analysis on Herantis, subsequent to the share issue of May 2020: [Directed share offering](#)